ENTITY

Halozyme Therapeutics (HALO US)

24
Analysis
Health Care • United States
Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The Company's platform technology is based on recombinant human hyaluronidase plus additional enzymes. Halozyme applies its technology to its proprietary programs and to partnerships with pharmaceutical companies.
more
bullish•S&P 500 INDEX
•10 Feb 2021 10:34

U.S. Equity Strategy: Bullish Outlook Intact

The action we are seeing in broad indexes, Sectors, and in market dynamics continues to support our overall bullish outlook. Continue to buy dips.

Logo
302 Views
Share
bullish•S&P 500 INDEX
•06 May 2020 03:02

U.S. Equities: Upside Momentum Lost, But Not Breaking Down

In today's report we highlight key levels and several metrics we are watching that will provide us clues as to where the S&P 500 is headed...

Logo
570 Views
Share
bullish•S&P 500 INDEX
•20 Dec 2019 06:10

MSCI ACWI, STOXX 600 Breaking Out, Adding Fuel for Further U.S. Equity Market Rally

In today’s report we reiterate our bullish U.S. investment thesis, recap significant technical levels across indexes, and highlight attractive...

Logo
713 Views
Share
x